Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice
Neuropsychopharmacology Reports · 2023
DOI: 10.1002/npr2.12316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2023. Verfasst von Naoki Amada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of CNS Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Major Depressive Disorder. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical.
Abstract (Originalsprache)
Aim
Selective serotonin reuptake inhibitors (SSRIs) are used to treat major depressive disorder (MDD) and other psychiatric disorders (e.g., obsessive compulsive disorder, social anxiety disorder, and panic disorder). In MDD treatment, SSRIs do not show remission in approximately 30% of patients, indicating a need for a better treatment option. Forced swimming test (FST) is a behavioral assay to evaluate depression‐like behavior and antidepressant efficacy in rodents. In the present study, we evaluated the combination effect of brexpiprazole with SSRIs on FST in mice, in order to investigate their synergistic effect.
Methods
Brexpiprazole (0.003 mg/kg) was intraperitoneally injected to mice 15 min before testing. Escitalopram (10 mg/kg), fluoxetine (75 mg/kg), paroxetine (10 mg/kg), or sertraline (15 mg/kg) were orally administered to mice 60 min before testing. Then, the mice were placed in water and immobility time was measured. Data from animals treated with escitalopram, fluoxetine, paroxetine, and sertraline were pooled as SSRI‐treated group data.
Results
Combination treatment of brexpiprazole with SSRIs reduced immobility time in FST more than vehicle or each single treatment. A significant interaction effect was confirmed in the combination of brexpiprazole and SSRIs ( p = 0.0411).
Conclusion
Efficacy of adjunctive brexpiprazole has already been demonstrated in clinical trials in MDD patients not adequately responding to antidepressants including escitalopram, fluoxetine, paroxetine, and sertraline. The synergistic antidepressant‐like effect of brexpiprazole with SSRIs found in this study supports the already known clinical findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of CNS Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
- Department of Lead Discovery Research, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
- Pharmaceutical Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
ORCID-Profile: Naoki Amada, Tetsuro Kikuchi
Förderung
- Otsuka Pharmaceutical
Zitieren
APA
Amada, N., Hirose, T., Suzuki, M., Kakumoto, Y., Futamura, T., Maeda, K., & Kikuchi, T. (2023). Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12316
Vancouver
Amada N, Hirose T, Suzuki M, Kakumoto Y, Futamura T, Maeda K, et al. Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology Reports. 2023. doi:10.1002/npr2.12316
BibTeX
@article{Amada2023,
author = {Amada, Naoki and Hirose, Tsuyoshi and Suzuki, Mikio and Kakumoto, Yusuke and Futamura, Takashi and Maeda, Kenji and Kikuchi, Tetsuro},
title = {Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice},
journal = {Neuropsychopharmacology Reports},
year = {2023},
doi = {10.1002/npr2.12316}
}
EUVIMED